Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

administered daily. Patients in the first cohort will receive a dose of XL184 that is below the maximum tolerated dose (MTD) identified in the ongoing phase 1 trial of XL184, in combination with erlotinib. Subsequent cohorts will receive erlotinib in combination with escalating doses of XL184 until the MTD is reached. In the phase 2 portion of the study, patients will be randomized to receive XL184 at the MTD alone or in combination with erlotinib. Additionally, correlative studies will evaluate MET amplification and EGFR mutational status. MET and EGFR signaling activity will be assessed in tumor and surrogate tissue.

Data from an ongoing phase 1 trial of XL184 in patients with advanced malignancies were presented in October 2007 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract #A152). Investigators reported that anti-tumor activity had been observed in a variety of cancers at doses that are not associated with significant toxicity. There were 33 patients available for safety, pharmacokinetic and tumor response analyses as of the June 22, 2007 cutoff; further data were also provided for six additional patients after the cutoff. Of seven patients with medullary thyroid cancer (MTC), three had partial responses (two confirmed and one unconfirmed) as of the date of the AACR-NCI- EORTC Conference. In addition, as of such date, six of the seven patients had tumor shrinkage and one had non-measurable disease. All seven assessable patients with MTC experienced a rapid decrease in plasma levels of calcitonin, a marker frequently elevated in MTC, and six of the seven patients had a decrease in the tumor marker carcinoembryonic antigen. All seven MTC patients remain on study. In addition, one patient with a neuroendocrine tumor has an unconfirmed partial response. In total, 15 patients with various malignancies have had stable disease lasting from 3 - 20 months, including nine patients with stable disease for m
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. (NYSE ... drug candidates targeting specific pathogens that cause serious infections ... unusual market activity in the Company,s stock, the NYSE ... with its usual practice. The Company stated that its ... About Synthetic Biologics, Inc. Synthetic ...
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... YORK , July 29, 2014  Longtime industry ... Caremark Rx, Drew Crawford today announced the ... the leading independent media source dedicated to delivering fair, ... on the pharmacy benefit management (PBM) industry .  ... of, and context behind, industry news.   The outlet will ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2
(Date:7/30/2014)... Computer Resources of America, Inc. (CRA), an ... City, has been awarded the contract to rewire the ... large global bank. The bank is a global leader ... of CRA said, “Being awarded this contract with our ... what has already been a successful and deep relationship. ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review ... for men who want to discover how to increase their ... within a few months. Inside this book, learners will discover ... and avoid the aches and pains. , Vkool reveals in ... learners the reason why stretching and warming up is so ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... VisitandCare.com today announced that several ... the company’s exclusive network to help couples struggling with ... — as top fertility clinics in Spain, Switzerland, Greece, ... and successful IVF treatments. , The exclusive selection of ... by professionals at VisitandCare.com. The goal is to connect ...
(Date:7/29/2014)... 2014 Phytceramides are a natural anti-aging tool for ... new book. , Today is the last day to nab a ... Best . The book is also sold in hard copy. , ... that Phytoceramides were so new and very unknown in ... book now," says Kathy Heshelow, founder of Sublime Beauty®. "It is ...
Breaking Medicine News(10 mins):Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3
... Services, Treatment and Prevention Available--MINNEAPOLIS, April 29 ... health care centers in the United States, is ... flu (H1N1) and provide rapid testing services, treatment ... medically appropriate. MinuteClinic is coordinating with local ...
... 29 Grupo Aeroportuario del Sureste, S.A.B. de C.V. ... first privatized airport group in Mexico and operator of Cancun ... today that on April 26, 2009 the Mexican Secretary of ... in Mexico. On April 28, 2009 the World Health Organization ...
... BOTHELL, Wash., April 29 SCOLR Pharma, Inc. (NYSE Alternext ... financial results on Friday, May 1, 2009, at 8:30 a.m. ... Pharma, will host the conference call at 11:30 a.m. Eastern, ... other interested parties may participate in the conference call by ...
... Survey finds many cities have dangerously high levels of pollution ... of the nation,s population, 186.1 million people to be exact, ... air pollution, new research shows. , "Six out of ten ... the emergency room, to shape how kids, lungs develop and ...
... 2009 Relationships are difficult and most of us probably ... when discussing stressful issues, like home finances, is an impossible ... take the "edge" off these discussions? The biology of ... research on social cognition conducted in animals is now informing ...
... Michigan physicians are the first in the nation ... through a new partnership announced today by the American ... with Compuware,s Covisint subsidiary. This partnership builds on ... the AMA announced its agreement with Covisint to develop ...
Cached Medicine News:Health News:MinuteClinic is Educating Consumers About Swine Flu 2Health News:MinuteClinic is Educating Consumers About Swine Flu 3Health News:SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern 2Health News:More Than Half of Americans Living with Dirty Air 2Health News:More Than Half of Americans Living with Dirty Air 3Health News:Oxytocin: Love potion #1? 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... qualitative differential detection of ... and an antigen that is ... of malaria:plasmodium falciparum (P.f), plasmodium ... and Plasmodium malariae (P.m) in ...
Medicine Products: